Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX · NASDAQ Global Select
-$6.43 today
Vol 2.67M · Avg 1.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
21.2%
avg 11.6%
ROIC
18.1%
avg 7.6%
ROA
15.1%
avg 10.6%
Analysis
ROE is currently the strongest return metric at 21.2% versus its period average of 11.6%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Reshma Kewalramani FASN | Chief Executive Officer, President & Director | $6.14M | — | 53 | $137,878.00 | 0.05% |
Charles F. Wagner Jr. | Executive Vice President, Chief Operating Officer & Chief Financial Officer | $2.99M | — | 58 | $47,042.00 | 0.02% |
Mark Bunnage D.Phil | Executive Vice President & Chief Scientific Officer | $2.39M | — | 57 | $7,284.00 | <0.01% |
Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | $2.27M | — | 63 | $16,953.00 | <0.01% |
Ourania Tatsis | Executive Vice President and Chief Regulatory & Quality Officer | $2.07M | — | 56 | $46,763.00 | 0.02% |
Amit K. Sachdev | Executive Vice President & Chief Patient and External Affairs Officer | $1.88M | — | 58 | $55,570.00 | 0.02% |
Jeffrey Marc Leiden | Executive Chairman | — | — | 70 | $34,797.00 | 0.01% |
Kristen C. Ambrose | Senior Vice President & Chief Accounting Officer | — | — | 49 | $6,624.00 | <0.01% |
Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | — | — | 48 | $20,729.00 | <0.01% |
Susie Lisa | Senior Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
83
$136.87M
Net Sentiment
$136.87M
Net selling
Most Active
Kewalramani Reshma
13 transactions
1–10 of 83
Analysis
Insiders reported 0 buys worth $0.00 and 83 sells worth $136.87M over the last 12 months. That adds up to net selling of $136.87M. Kewalramani Reshma was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A12 analysts |
| Revenue | N/A | N/A | -12.2% | +21.6% (15yr)12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Recent growth has been strongest in Revenue at -12.2% over three years. Forward estimates point to Revenue at +21.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$125.68B
Stryker Corporation
NYSE:SYK
$118.98B
Bristol-Myers Squibb Company
NYSE:BMY
$110.01B
GSK plc
NYSE:GSK
$101.86B
Sanofi
NASDAQ:SNY
$101.42B
Medtronic plc
NYSE:MDT
$101.25B
McKesson Corporation
NYSE:MCK
$87.89B
HCA Healthcare, Inc.
NYSE:HCA
$83.43B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$61.95B
argenx SE
NASDAQ:ARGX
$54.50B
Who manages VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) lists 10 active executives. The top listed executive is Carmen Bozic, Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer.
Are VRTX insiders buying or selling?
Recent insider activity shows net selling of $180.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.